Gossamer Bio Faces Securities Class Action After Phase 3 Trial Failure Leads to 80% Stock Plunge
On February 23, 2026, Gossamer Bio, Inc. (NASDAQ: GOSS) shocked the market with the announcement that results from its Phase 3 PROSERA trial had fallen short of expectations. The trial aimed to assess the effectiveness of seralutinib in treating pulmonary arterial hypertension (PAH), but failed to meet its primary endpoint, resulting in a staggering 80% drop in the company’s stock value. Following this announcement, a securities class action lawsuit was lodged against Gossamer Bio and one of its executives, with the goal of representing investors who acquired Gossamer’s securities between June 16, 2025, and February 20, 2026. The lawsuit arises during a tumultuous time for the company, as its actions and disclosures regarding the Phase 3 PROSERA trial are now under intense scrutiny.
According to the complaint filed by Hagens Berman Sobol Shapiro LLP, Gossamer’s management previously emphasized the groundbreaking nature of seralutinib, portraying it as a potential first-in-class treatment with the ability to open up a multi-billion dollar market across various indications. As recently as November 2025, investors expressed optimism following statements from management that drew parallels between seralutinib and the successful Merck Phase 3 STELLAR study of sotatercept for PAH. The management had assured investors that they were adhering to stringent patient recruitment protocols and believed the trial would demonstrate statistically significant results by focusing on regions where prior studies showed superior efficacy.
However, concerns arose when it was revealed that Gossamer allegedly disregarded or failed to disclose critical information regarding trial design issues and the performance of patients in Latin America — a region that had shown encouraging placebo responses. During the call that followed the trial failure announcement, Gossamer's management noted that the overall treatment effect had been "materially diluted" by an excessive placebo response seen in Latin America. They communicated that patients in that region were performing better on placebo than expected, further complicating the results.
Investors who had high hopes for seralutinib were left disillusioned after the trial results were published. Following the announcement of the failure, Gossamer’s share price plummeted by 80%, drastically affecting shareholders' investments. Furthermore, by April 9, 2026, Gossamer disclosed that it had failed to meet the minimum share bid price required for continued listing on the Nasdaq Global Select Market, indicating potential problems for the company moving forward.
The lawsuit expressed concerns over the adequacy of disclosures regarding trial design and patient entry criteria. Moreover, the firm leading the investors’ class action emphasized the potential misrepresentation of data that may have misled investors about the trial's efficacy. Reed Kathrein, a partner at Hagens Berman, stated that the firm is focused on evaluating claims that Gossamer misled its investors about the PROSERA trial design.
In light of these serious allegations, the law firm encouraged any investors who incurred substantial losses to submit their claims. They also urged individuals with relevant non-public information regarding Gossamer Bio to consider cooperating with the investigation, and even pointed out possible rewards through the SEC Whistleblower program.
This class action has brought attention to Gossamer Bio not only for its previous claims made about seralutinib but also for the larger implications of shareholder rights and corporate disclosure policies. As the litigation proceeds, investors at Gossamer Bio await any favorable developments while the light is brightly shining on a company that had once promised groundbreaking innovations. Gossamer faces an uphill battle in regaining investor trust and stabilizing its financial standing after this tumultuous phase.
In summary, Gossamer Bio's trial failures and significant stock decline have led to a class action lawsuit, raising important questions about investor protections and ethical disclosures in the biotech industry. As further revelations unfold, the action taken by shareholders will be closely monitored by market participants and legal analysts alike.
According to the complaint filed by Hagens Berman Sobol Shapiro LLP, Gossamer’s management previously emphasized the groundbreaking nature of seralutinib, portraying it as a potential first-in-class treatment with the ability to open up a multi-billion dollar market across various indications. As recently as November 2025, investors expressed optimism following statements from management that drew parallels between seralutinib and the successful Merck Phase 3 STELLAR study of sotatercept for PAH. The management had assured investors that they were adhering to stringent patient recruitment protocols and believed the trial would demonstrate statistically significant results by focusing on regions where prior studies showed superior efficacy.
However, concerns arose when it was revealed that Gossamer allegedly disregarded or failed to disclose critical information regarding trial design issues and the performance of patients in Latin America — a region that had shown encouraging placebo responses. During the call that followed the trial failure announcement, Gossamer's management noted that the overall treatment effect had been "materially diluted" by an excessive placebo response seen in Latin America. They communicated that patients in that region were performing better on placebo than expected, further complicating the results.
Investors who had high hopes for seralutinib were left disillusioned after the trial results were published. Following the announcement of the failure, Gossamer’s share price plummeted by 80%, drastically affecting shareholders' investments. Furthermore, by April 9, 2026, Gossamer disclosed that it had failed to meet the minimum share bid price required for continued listing on the Nasdaq Global Select Market, indicating potential problems for the company moving forward.
The lawsuit expressed concerns over the adequacy of disclosures regarding trial design and patient entry criteria. Moreover, the firm leading the investors’ class action emphasized the potential misrepresentation of data that may have misled investors about the trial's efficacy. Reed Kathrein, a partner at Hagens Berman, stated that the firm is focused on evaluating claims that Gossamer misled its investors about the PROSERA trial design.
In light of these serious allegations, the law firm encouraged any investors who incurred substantial losses to submit their claims. They also urged individuals with relevant non-public information regarding Gossamer Bio to consider cooperating with the investigation, and even pointed out possible rewards through the SEC Whistleblower program.
This class action has brought attention to Gossamer Bio not only for its previous claims made about seralutinib but also for the larger implications of shareholder rights and corporate disclosure policies. As the litigation proceeds, investors at Gossamer Bio await any favorable developments while the light is brightly shining on a company that had once promised groundbreaking innovations. Gossamer faces an uphill battle in regaining investor trust and stabilizing its financial standing after this tumultuous phase.
In summary, Gossamer Bio's trial failures and significant stock decline have led to a class action lawsuit, raising important questions about investor protections and ethical disclosures in the biotech industry. As further revelations unfold, the action taken by shareholders will be closely monitored by market participants and legal analysts alike.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.